Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Exo-Biomed currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a single distinct examiner, CASEY SHEA HAGOPIAN, and is located in 1 distinct art unit. The prosecution for this portfolio is currently limited to this active proceeding.
The fact that there is a lone pending matter indicates a very narrow window of active prosecution at this time. CASEY SHEA HAGOPIAN is the only individual currently reviewing the company's work. Furthermore, the activity is restricted to a single art unit, which simplifies the procedural landscape for the company's legal representatives.
With the current workload and the sole examiner, the company's immediate success in the Biotechnology & Pharmaceuticals area depends on this specific interaction. The busiest examiner manages all of the company's current workload at the patent office. This focus allows for a deep analysis of the individual's past behavior and the specific division's trends.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGOPIAN, CASEY SHEA | 1 | 54.2% | +33.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18982079 | PHYSIOLOGICALLY AND MECHANICALLY BIOCOMPATIBLE ARTIFICIAL PANCREAS AND PHYSICALLY CROSSLINKED POLYVINYL ALCOHOL HYDROGELS AND SOLIDS FROM WHICH THE BIOARTIFICIAL PANCREAS IS MANUFACTURED | HAGOPIAN, CASEY SHEA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18982079 | PHYSIOLOGICALLY AND MECHANICALLY BIOCOMPATIBLE ARTIFICIAL PANCREAS AND PHYSICALLY CROSSLINKED POLYVINYL ALCOHOL HYDROGELS AND SOLIDS FROM WHICH THE BIOARTIFICIAL PANCREAS IS MANUFACTURED | HAGOPIAN, CASEY SHEA | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18982079 | PHYSIOLOGICALLY AND MECHANICALLY BIOCOMPATIBLE ARTIFICIAL PANCREAS AND PHYSICALLY CROSSLINKED POLYVINYL ALCOHOL HYDROGELS AND SOLIDS FROM WHICH THE BIOARTIFICIAL PANCREAS IS MANUFACTURED | HAGOPIAN, CASEY SHEA | 1617 | §103§112 | Non-Final OA | — | Pending | Dec 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialExo-Biomed has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Casey Shea Hagopian has the most, with 1 of Exo-Biomed's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.